Alumis (ALMS) Asset Utilization Ratio (2025 - 2026)
Alumis' (ALMS) quarterly Asset Utilization Ratio came in at 0.02 in Q2 2026, down 67.99% quarter-over-quarter from 0.05 in Q4 2025.
Powered by 
Analysis
Alumis (ALMS) Asset Utilization Ratio (2025 - 2026) Analysis & Trends
Alumis (ALMS) has reported Asset Utilization Ratio for 2 consecutive years, with 0.02 the latest figure, recorded in Q2 2026.
- On a quarterly basis, Asset Utilization Ratio changed N/A year-over-year to 0.02 in Q2 2026; TTM through Jun 2026 was 0.02, a N/A change from a year earlier, with the FY2025 full-year figure at 0.06, changed N/A from the prior year.
- Asset Utilization Ratio was 0.02 for Q2 2026 at Alumis, down from 0.05 in the prior quarter.
- Over five years, Asset Utilization Ratio peaked at 0.05 in Q4 2025 and troughed at 0.02 in Q2 2026.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Asset Util. (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 208.48 Bn | 194.49 Bn | 7.24 Bn | 0.40 |
| 2 | Gilead Sciences | 186.29 Bn | 183.02 Bn | 6.22 Bn | 0.58 |
| 3 | Vertex Pharmaceuticals | 128.79 Bn | 120.93 Bn | 2.84 Bn | 0.47 |
| 4 | Regeneron Pharmaceuticals | 80.66 Bn | 72.67 Bn | 3.93 Bn | 0.38 |
| 5 | Moderna | 61.46 Bn | 56.32 Bn | 52.00 Mn | 0.20 |
| 6 | Argenx Se | 61.28 Bn | 56.10 Bn | 1.37 Bn | - |
| 7 | Alnylam Pharmaceuticals | 32.04 Bn | 28.73 Bn | 992.69 Mn | 0.90 |
| 8 | Biogen | 31.84 Bn | 30.56 Bn | 1.96 Bn | 0.33 |
| 9 | Roivant Sciences | 28.74 Bn | 29.43 Bn | 1.16 Mn | 0.00 |
| 10 | Alumis | 966.94 Mn | 464.65 Mn | - | 0.02 |